Trial Profile
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms PANTHER
- Sponsors Takeda Oncology
- 08 Mar 2024 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 04 Jan 2024 Planned End Date changed from 29 Dec 2023 to 30 Jun 2024.
- 22 Aug 2023 Planned End Date changed from 30 Jun 2023 to 29 Dec 2023.